Abu Dhabi Health Data Services (ADHDS), a component of M42’s Digital Health Solutions (DHS) platform, has announced a new collaboration with Syndesis Health. This partnership aims to advance artificial intelligence (AI)-driven genomic analytics and drug discovery.

The collaboration is set to leverage Syndesis Health’s expertise in data science and analytics to provide enhanced genomic insights. This initiative is expected to improve patient outcomes by enabling more personalized and effective treatment options.

Officials from ADHDS highlighted that the integration of AI in genomic analytics will streamline the drug discovery process, making it faster and more efficient. This move is seen as a significant step forward in the healthcare sector, particularly in precision medicine.